Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) EPS (Basic) (2020 - 2025)

Caribou Biosciences has reported EPS (Basic) over the past 6 years, most recently at -$0.28 for Q4 2025.

  • Quarterly EPS (Basic) rose 28.21% to -$0.28 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.59 through Dec 2025, up 3.64% year-over-year, with the annual reading at -$1.59 for FY2025, 3.64% up from the prior year.
  • EPS (Basic) was -$0.28 for Q4 2025 at Caribou Biosciences, up from -$0.3 in the prior quarter.
  • Over five years, EPS (Basic) peaked at -$0.12 in Q3 2023 and troughed at -$1.39 in Q1 2021.
  • The 5-year median for EPS (Basic) is -$0.44 (2022), against an average of -$0.5.
  • The largest YoY upside for EPS (Basic) was 81.55% in 2021 against a maximum downside of 531.82% in 2021.
  • A 5-year view of EPS (Basic) shows it stood at -$0.31 in 2021, then crashed by 45.16% to -$0.45 in 2022, then increased by 11.11% to -$0.4 in 2023, then increased by 2.5% to -$0.39 in 2024, then increased by 28.21% to -$0.28 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's EPS (Basic) are -$0.28 (Q4 2025), -$0.3 (Q3 2025), and -$0.58 (Q2 2025).